Merck’s Enflonsia is part of the company’s growing vaccine portfolio, which has become an increasingly important revenue segment alongside its oncology and other pharmaceutical divisions.

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its Hold rating and $100 price target on Merck & Co., Inc. (NYSE:MRK) after a ...

Q2 2025 Earnings Call Transcript July 29, 2025 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, ...

Merck plans to make ENFLONSIA available for ordering by physicians and health care administrators in July 2025, with shipments to be delivered before the start of the 2025-2026 RSV season.

Merck plans to make ENFLONSIA available for ordering by physicians and health care administrators in July 2025, with shipments to be delivered before the start of the 2025-2026 RSV season.

Merck plans to make Enflonsia available for physicians and healthcare administrators to order in July 2025. Shipments will be delivered before the start of the 2025-2026 RSV season.

Advisory Committee on Immunization Practices (ACIP) recommendation expands respiratory syncytial virus (RSV) prevention options: Merck’s Enflonsia is now recommended for infants under eight months of ...

RAHWAY, N.J., June 26, 2025 -- (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention (CDC) ...

Merck’s Enflonsia is part of the company’s growing vaccine portfolio, which has become an increasingly important revenue segment alongside its oncology and other pharmaceutical divisions. The ACIP ...